ISPOR Russia St. Petersburg Chapter Recognized with the ISPOR Outstanding Regional Chapter Award – Congratulations!
The Award program recognized outstanding contribution and leadership of ISPOR Regional Chapters in advancing ISPOR’s mission in ISPOR global regions – Asia, Latin America, and Europe, Middle East, and Africa. ISPOR also congratulates ISPOR Colombia and Mexico Regional Chapters for being recognized with the Award.
Chapter President, Prof. Alexey Kolbin, who received the award during plenary session at ISPOR Europe 2018 in Barcelona, Spain, was featured in the November/December 2018 issue of Value &Outcomes Spotlight. In an interview with the journal, Prof. Kolbin reflected on the Chapter’s significance and contribution to the development of HEOR supporting better health decision making in his country. The interview article is available here.
About the Award
ISPOR staff assesses the Chapters contributions by applying eligibility and selection criteria in their review of the information available from the Chapter Annual Reports, chapter input to the ISPOR publications and ISPOR activities throughout the year. The award consists of a trophy, an amount of 1000USD per winning Chapter (available as a credit against the future Chapter educational events), interview in VOS and a complimentary Annual European Congress registration for the Chapter delegate who is accepting the award on behalf of the Chapter. More about the award is available here.
Research Activities of ISPOR Russia St. Petersburg Chapter
Monitoring of the Reimbursement Lists in Russia
One of the main scientific activities of ISPOR Russia St. Petersburg Chapter in 2017 was to continue the monitoring of the reimbursement lists in Russia.
In Russia the cost-effectiveness threshold is not yet introduced into the procedure of reimbursement lists revision and is not used as the criteria of inclusion or exclusion of drugs as in many other countries.
Due to the fact that in 2016 the reimbursement lists were not yet revised, ISPOR Russia St. Petersburg Chapter researchers focused on the data of the last two revisions from 2014 and 2015. They took the health economic data from the dossiers of anti-cancer drugs with ATC codes L01 and L02 submitted during that period. For each health economic evaluation they analyzed number of LYG, progression-free LYG, QALYs; incremental cost per one LYG, progression-free LYG and QALY.
The main goal was to calculate the median ICER for anti-cancer drugs included and rejected from the reimbursement and then compare it with the CE threshold in Russia. The median cost of one LYG, progression-free LYG and one QALY gained showed to be higher comparing to the willingness to pay a threshold in Russia by 1,5%, 125% and 50%, consequently. ICER/LYG did not differ between the drugs included and rejected from the reimbursement, ICER/QALY was slightly even higher in the group of included drugs compared to the group of rejected ones. This analysis was published in the Russian journal and the data is open.
The conclusion drawn from the work is that in Russia the drugs entered into the reimbursement system during the last two revisions have ICER/LYG almost equal to the threshold. (Reported by ISPOR Russia St. Petersburg Chapter)
|Alexey Kolbin, MD, PhD|
|President-Elect||Sergey Zyryanov, MD, PhD|
Alexey Kurylev, MD